Bristol-Myers (BMY) Wins Ruling Blocking Generic Plavix
More News related to BMY
- Citi Initiates Coverage on Bristol-Myers Squibb (BMY) with a Neutral
- *Revised* Analyst Reports for First Horizon National Corporation, Bristol-Myers Squibb Company, Continental Airlines Inc., and Goldcorp Inc.
- Bristol-Myers Squibb to Announce Results for the Second Quarter of 2008 on July 24
- Matrix USA Rating Changes 7/9
- Pro-Pharmaceuticals and Sanghyon Chemical Ink Historic Agency Agreement
More News related to SNY
- Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program
- SAFE-BioPharma Roaming Digital ID Is First to Be Accepted by Federal Bridge
- FDA Licenses Sanofi Pasteur's Pediatric Combination Vaccine, Pentacel
- U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R)
- U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R)
Bristol-Myers Squibb Co. (NYSE: BMY) and Sanofi-Aventis (NYSE: SNY) won a trial blocking generic competition on top selling blood-thinner Plavix. The court rejected Apotex\'s claim that the patent is invalid or unenforceable.
Related Categories
FDAStocks Mentioned
-0.31
+0.76Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
